巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Belite Bio

    BLTE
    30.160
    3.560
    10.56%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Belite Bio - 延遲價格・最後更新於 28/06 9:02
    最高位
    34.500
    最低位
    29.940
    開市價
    --
    前收市價
    33.720
    成交量(千)
    2.80
    成交額(百萬)
    0.89
    買入
    23.220
    賣出
    39.530
    每手股數
    --
    市值(百萬)
    726.71
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    35.200 - 8.800
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Belite Bio
    證券代碼
    BLTE.US
    所屬板塊
    Biotechnology
    公司業務
    Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
    發行量
    24095317
    公司總部
    5820 Oberlin Drive, Suite 101
    公司網址
    https://www.belitebio.com
    公司電話
    +1 858 246-6240
    暫無內容

    關於

    Belite Bio(BLTE.US)所屬的行業板塊為Biotechnology。
    Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
    詳細公司背景可參考: https://www.belitebio.com